{
    "clinical_study": {
        "@rank": "154770", 
        "arm_group": {
            "arm_group_label": "Arm 1", 
            "arm_group_type": "Experimental", 
            "description": "SAR405838  and pimasertib in escalating doses"
        }, 
        "brief_summary": {
            "textblock": "Primary Objectives:\n\n      To determine the recommended Phase 2 dose of SAR405838 / pimasertib combination therapy in\n      patients with solid tumors.\n\n      To assess the anti-tumor activities of SAR405838 / pimasertib in patients with solid tumors.\n\n      Secondary Objectives:\n\n      To characterize the pharmacokinetic profile of SAR405838 and pimasertib.\n\n      To evaluate the pharmacodynamic effect of the SAR405838 and pimasertib.\n\n      To characterize genetic status in tumor tissue and circulating tumor DNA."
        }, 
        "brief_title": "A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasm Malignant", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The duration of the study for an individual patient will include a period to assess\n      eligibility of up to 4 weeks, a treatment period of at least 6 weeks of study treatment, and\n      an end-of-study visit at least 30 days (or until the patient receives another anti-cancer\n      therapy, whichever is shorter) following the last administration of study drug."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically or cytologically confirmed diagnosis of a solid tumor.\n\n          -  Presence of locally advanced or metastatic disease with at least one measurable\n             lesion.\n\n          -  Ability to provide written informed consent. Evidence of a personally signed informed\n             consent.\n\n        Exclusion criteria:\n\n          -  Age <18 years.\n\n          -  Eastern Cooperative Oncology Group performance status  of >1.\n\n          -  Inadequate functions of bone marrow, liver, and kidney.\n\n          -  Positive pregnancy test in women of child-bearing potential.\n\n          -  Pregnancy or breast-feeding.\n\n          -  Extensive prior radiotherapy.\n\n          -  The patient has retinal degenerative disease, history of uveitis, or history of\n             retinal vein occlusion, or history of retinal detachment, or has medically relevant\n             abnormalities identified on screening ophthalmologic examination.\n\n          -  Prior history of myositis or rhabdomyolysis.\n\n          -  Recent major surgery or trauma, unhealing/open wounds.\n\n          -  The patient has had congestive heart failure, unstable angina, a myocardial\n             infarction, cardiac conduction abnormality or pacemaker or a stroke within 3 months\n             of entering the study.\n\n          -  The patient has a baseline corrected QT interval (QTc) >480 ms or left ventricular\n             ejection fraction (LVEF) <50% or less than the lower limit of normal.\n\n          -  The patient has a previously-identified allergy or hypersensitivity to components of\n             the study treatment formulations.\n\n          -  Unwillingness or inability to comply with scheduled visits, drug administration plan,\n             laboratory tests, other study procedures, and study restrictions.\n\n          -  Unwillingness, if not postmenopausal or surgically sterile, to abstain from sexual\n             intercourse or employ an effective barrier or medical method of contraception during\n             the study drug administration and follow-up periods.\n\n          -  Recent history of acute pancreatitis.\n\n          -  Clinically significant illness, medical condition, surgical history, physical\n             finding, or laboratory abnormality that could affect the safety of the patient; alter\n             the absorption of the study drugs; or impair the assessment of study results.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01985191", 
            "org_study_id": "TCD13388", 
            "secondary_id": [
                "2013-002325-33", 
                "U1111-1144-8349"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "description": "Pharmaceutical form:capsule\nRoute of administration: oral", 
                "intervention_name": "SAR405838", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 1", 
                "description": "Pharmaceutical form: capsule\nRoute of administration: oral", 
                "intervention_name": "Pimasertib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Villejuif Cedex", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Investigational Site Number 250001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066 CX"
                    }, 
                    "name": "Investigational Site Number 528001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3075 EA"
                    }, 
                    "name": "Investigational Site Number 528003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 CX"
                    }, 
                    "name": "Investigational Site Number 528002"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study of Combination Therapy With SAR405838 and Pimasertib in Patients With Advanced Cancer", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Committee for the Protection of Personnes", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "SAR405838 / pimasertib RP2D assessed by dose-limiting toxicities and pharmacological activities", 
                "safety_issue": "No", 
                "time_frame": "6 weeks for each patient at each dose level"
            }, 
            {
                "measure": "Changes of tumor dimension by imaging", 
                "safety_issue": "No", 
                "time_frame": "At least 3 months for each patient"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01985191"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall safety profile of SAR405838 / pimasertib, number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Throughout the study (~12 months)"
            }, 
            {
                "measure": "Pharmacokinetic parameters for both SAR405838 and pimasertib: the maximum concentration in blood (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "3 months for each patient"
            }, 
            {
                "measure": "Pharmacokinetic parameters for both SAR405838 and pimasertib: time to the maximum concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "3 months for each patient"
            }, 
            {
                "measure": "Pharmacokinetic parameters for both SAR405838 and pimasertib area under the curve (AUC), etc.", 
                "safety_issue": "No", 
                "time_frame": "3 months for each patient"
            }, 
            {
                "measure": "Biomarker changes in response to SAR405838 / pimasertib treatment", 
                "safety_issue": "No", 
                "time_frame": "3 months for each patient"
            }, 
            {
                "measure": "Genetic status in tumor tissue", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Changes of the genetic status of circulating tumor DNA", 
                "safety_issue": "No", 
                "time_frame": "Baseline and until disease progression (~12 months)"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}